Fetal growth restriction in diabetic pregnancy: a retrospective single-center study

Abstract

BACKGROUND: The high risk of adverse maternal and perinatal complications in patients with fetal growth restriction and diabetes mellitus requires a detailed assessment of the major risk factors and outcomes.

AIM: The aim of this study was to determine the main risk factors for fetal growth retardation in pregnant women with pregestational and gestational diabetes mellitus, and to assess obstetric and perinatal outcomes in these patients.

MATERIALS AND METHODS: We conducted a retrospective single-center cohort study at the premises of the Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott, Saint Petersburg, Russia. The study included 103 patients with type 1 diabetes mellitus, type 2 diabetes mellitus, or gestational diabetes mellitus with fetal growth retardation who delivered a singleton neonate from January 2017 to December 2021. Based on the antenatal diagnosis, the patients were divided into the following comparison groups: group I — early fetal growth retardation (n = 29), group II — late fetal growth retardation (n = 27), group III — small for gestational age (n = 47). Relative risk calculations were used to assess the contribution of risk factors and the risk of developing secondary outcomes.

RESULTS: Pregestational diabetes mellitus was the major risk factor for early fetal growth retardation development (relative risk 1.91; 95% confidence interval 1.04–3.50); especially type 1 diabetes mellitus (relative risk 1.64; 95% confidence interval 1.02–2.74) and more than 10 years of pregestational diabetes mellitus duration (relative risk 2.62; 95% confidence interval 1.12–6.17). Chronic hypertension increases the risk of early fetal growth retardation (relative risk 2.11; 95% confidence interval 2.21–3.68), while gestational hypertension was a significant risk factor for late fetal growth retardation development (relative risk 1.81; 95% confidence interval 1.01–3.70). Preeclampsia is associated with both early and late forms of fetal growth retardation. Maternal characteristics, such as age over 35 years, obesity, and in vitro fertilization pregnancy, increased the risk of early fetal growth retardation development. In turn, the presence of fetal growth retardation in patients with diabetes mellitus is associated with increased risk of cesarean section, prolonged stay of the newborn in the neonatal intensive care unit (≥5 days), low Apgar scores (<7 at the 5th minute), and neonatal hypoglycemia. Early fetal growth retardation is a significant risk factor for preterm birth (relative risk 6.23; 95% confidence interval 2.87–13.42) and fetal distress (relative risk 5.51; 95% confidence interval 2.28–13.33).

CONCLUSIONS: Being associated with a highly increased risk of adverse obstetric and perinatal outcomes, early fetal growth retardation in diabetic pregnancy is related to pregestational diabetes mellitus, especially type 1 diabetes mellitus, with a long history, as well as with hypertension in pregnancy.

Keywords

diabetes mellitus / gestational diabetes / fetal growth retardation / small for gestational age

References

[1] Melamed N, Baschat A, Yinon Y, et al. FIGO (international Federation of Gynecology and obstetrics) initiative on fetal growth: best practice advice for screening, diagnosis, and management of fetal growth restriction. Int J Gynaecol Obstet. 2021; 152(Suppl. 1):3–57. DOI: 10.1002/ijgo.13522

[2] Melamed N., Baschat A., Yinon Y., et al. FIGO (international Federation of Gynecology and obstetrics) initiative on fetal growth: best practice advice for screening, diagnosis, and management of fetal growth restriction // Int. J. Gynaecol. Obstet. 2021. Vol. 152. Suppl. 1. P. 3–57. DOI: 10.1002/ijgo.13522

[3] Papastefanou I, Wright D, Nicolaides KH. Competing-risks model for prediction of small-for-gestational-age neonate from maternal characteristics and medical history. Ultrasound Obstet Gynecol. 2020;56(2):196–205. DOI: 10.1002/uog.22129

[4] Papastefanou I., Wright D., Nicolaides K.H. Competing-risks model for prediction of small-for-gestational-age neonate from maternal characteristics and medical history // Ultrasound. Obstet. Gynecol. 2020. Vol. 56. No. 2. P. 196–205. DOI: 10.1002/uog.22129

[5] Rashid CS, Bansal A, Simmons RA. Oxidative stress, intrauterine growth restriction, and developmental programming of type 2 diabetes. Physiology. 20181;33(5):348–359. DOI: 10.1152/physiol.00023.2018

[6] Rashid C.S., Bansal A., Simmons R.A. oxidative stress, intrauterine growth restriction, and developmental programming of type 2 diabetes // Physiology. 2018. Vol. 33. No. 5. P. 348–359. DOI: 10.1152/physiol.00023.2018

[7] Kapustin RV. Beremennost’ i sakharnyi diabet: patogenez, prognozirovanie akusherskikh i perinatal’nykh oslozhnenii, taktika vedeniya gestatsionnogo perioda i rodorazresheniya [dissertation abstract]. Saint Petersburg, 2021. (In Russ.). [cited 2022 Nov 12]. Available from: https://www.dissercat.com/content/beremennost-i-sakharnyi-diabet-patogenez-prognozirovanie-akusherskikh-i-perinatalnykh-oslozh

[8] Капустин Р.В. Беременность и сахарный диабет: патогенез, прогнозирование акушерских и перинатальных осложнений, тактика ведения гестационного периода и родоразрешения: автореф. диc. … д-ра мед. наук. Санкт Петербург, 2021. [дата обращения: 12.11.2022]. Доступно по ссылке: https://www.dissercat.com/content/beremennost-i-sakharnyi-diabet-patogenez-prognozirovanie-akusherskikh-i-perinatalnykh-oslozh.

[9] Piccoli GB, Clari R, Ghiotto S, et al. Type 1 diabetes, diabetic nephropathy, and pregnancy: a systematic review and meta-study. Rev Diabet Stud. 2013;10(1):6–26. DOI: 10.1900/RDS.2013.10.6

[10] Piccoli G.B., Clari R., Ghiotto S., et al. Type 1 diabetes, diabetic nephropathy, and pregnancy: a systematic review and meta-study // Rev. Diabet. Stud. 2013. Vol. 10. No. 1. P. 6–26. DOI: 10.1900/RDS.2013.10.6

[11] Adamczak L, Boron D, Gutaj P, et al. Fetal growth trajectory in type 1 pregestational diabetes (PGDM) — an ultrasound study. Ginekol Pol. 2021;92(2):110–117. DOI: 10.5603/GP.a2020.0136

[12] Adamczak L., Boron D., Gutaj P., et al. Fetal growth trajectory in type 1 pregestational diabetes (PGDM) — an ultrasound study // Ginekol. Pol. 2021. Vol. 92. No. 2. P. 110–117. DOI: 10.5603/GP.a2020.0136

[13] Capobianco G, Gulotta A, Tupponi G, et al. Materno-fetal and neonatal complications of diabetes in pregnancy: a retrospective study. J Clin Med. 2020;9(9). DOI: 10.3390/jcm9092707

[14] Capobianco G., Gulotta A., Tupponi G. et al. Materno-fetal and neonatal complications of diabetes in pregnancy: a retrospective study // J. Clin. Med. 2020. Vol. 9. No. 9. DOI: 10.3390/jcm9092707

[15] Gantenbein KV, Kanaka-Gantenbein C. Highlighting the trajectory fromintrauterine growth restriction tofuture obesity. Front Endocrinol. 2022;13. DOI: 10.3389/fendo.2022.1041718

[16] Gantenbein K.V., Kanaka-Gantenbein C. Highlighting the trajectory from intrauterine growth restriction to future obesity // Front. Endocrinol. 2022. Vol. 13. DOI: 10.3389/fendo.2022.1041718

[17] Bendix I, Miller SL, Winterhager E. Editorial: causes and consequences of intrauterine growth restriction. Front Endocrinol. 2020;11. DOI: 10.3389/fendo.2020.00205

[18] Bendix I., Miller S.L., Winterhager E. Editorial: causes and consequences of intrauterine growth restriction // Front. Endocrinol. 2020. Vol. 11. DOI: 10.3389/fendo.2020.00205

[19] Huynh J, Dawson D, Roberts D, et al. A systematic review of placental pathology in maternal diabetes mellitus. Placenta. 2015;36(2):101–114. DOI: 10.1016/j.placenta.2014.11.021

[20] Huynh J., Dawson D., Roberts D., et al. A systematic review of placental pathology in maternal diabetes mellitus // Placenta. 2015. Vol. 36. No. 2. P. 101–114. DOI: 10.1016/j.placenta.2014.11.021

[21] Starikov R, Inman K, Chen K, et al. Comparison of placental findings in type 1 and type 2 diabetic pregnancies. Placenta. 2014;35(12):1001–1006. DOI: 10.1016/j.placenta.2014.10.008

[22] Starikov R., Inman K., Chen K., et al. Comparison of placental findings in type 1 and type 2 diabetic pregnancies // Placenta. 2014. Vol. 35. No. 12. P. 1001–1006. DOI: 10.1016/j.placenta.2014.10.008

[23] Bhattacharjee D, Mondal SK, Garain P, et al. Histopathological study with immunohistochemical expression of vascular endothelial growth factor in placentas of hyperglycemic and diabetic women. J Lab Physicians. 2017;9(4):227–233. DOI: 10.4103/JLP.JLP_148_16

[24] Bhattacharjee D., Mondal S.K., Garain P., et al. Histopathological study with immunohistochemical expression of vascular endothelial growth factor in placentas of hyperglycemic and diabetic women // J. Lab .Physicians. 2017. Vol. 9. No. 4. P. 227–233. DOI: 10.4103/JLP.JLP_148_16

[25] Kapustin RV, Kopteyeva EV, Tral TG, et al. Placental morphology in different types of diabetes mellitus. Journal of Obstetrics and Women’s Diseases. 2021;70(2):13–26. (In Russ.). DOI: 10.17816/JOWD57149

[26] Капустин Р.В., Коптеева Е.В., Траль Т.Г., и др. Морфологическое строение плаценты при различных типах сахарного диабета // Журнал акушерства и женских болезней. 2021. Т. 70. № 2. C. 13–26. DOI: 10.17816/JOWD57149

[27] Gutaj P, Wender-Ozegowska E. Diagnosis and management of IUGR in pregnancy complicated by type 1 diabetes mellitus. Curr Diab Rep. 2016;16(5). DOI: 10.1007/s11892-016-0732-8

[28] Gutaj P., Wender-Ozegowska E. Diagnosis and management of IUGR in pregnancy complicated by type 1 diabetes mellitus // Curr. Diab. Rep. 2016. Vol. 16. No. 5. DOI: 10.1007/s11892-016-0732-8

[29] Kapustin R, Chepanov S, Kopteeva E, et al. Maternal serum nitrotyrosine, 8-isoprostane and total antioxidant capacity levels in pre-gestational or gestational diabetes mellitus. Gynecol Endocrinol. 2020; 36(Suppl. 1):36–42. DOI: 10.1080/09513590.2020.1816727

[30] Kapustin R., Chepanov S., Kopteeva E., et al. Maternal serum nitrotyrosine, 8-isoprostane and total antioxidant capacity levels in pre-gestational or gestational diabetes mellitus // Gynecol. Endocrinol. 2020. Vol. 36. Suppl. 1. P. 36–42. DOI: 10.1080/09513590.2020.1816727

[31] Langmia IM, Kräker K, Weiss SE, et al. Cardiovascular programming during and after diabetic pregnancy: role of placental dysfunction and IUGR. Front Endocrinol. 2019;10. DOI: 10.3389/fendo.2019.00215

[32] Langmia I.M., Kräker K., Weiss S.E., et al. Cardiovascular programming during and after diabetic pregnancy: role of placental dysfunction and IUGR // Front. Endocrinol. 2019. Vol. 10. DOI: 10.3389/fendo.2019.00215

[33] Brown MA, Magee LA, Kenny LC, et al. Hypertensive disorders of pregnancy: ISSHP classification, diagnosis, and management recommendations for international practice. Hypertension. 2018;72(1):24–43. DOI: 10.1161/HYPERTENSIONAHA.117.10803

[34] Brown M.A., Magee L.A., Kenny L.C., et al. Hypertensive disorders of pregnancy: isshp classification, diagnosis, and management recommendations for international practice // Hypertension. 2018. Vol. 72. No. 1. P. 24–43. DOI: 10.1161/HYPERTENSIONAHA.117.10803

[35] Gordijn SJ, Beune IM, Thilaganathan B, et al. Consensus definition of fetal growth restriction: a Delphi procedure. Ultrasound Obstet Gynecol. 2016;48(3):333–339. DOI: 10.1002/uog.15884

[36] Gordijn S.J., Beune I.M., Thilaganathan B., et al. Consensus definition of fetal growth restriction: a Delphi procedure // Ultrasound Obstet. Gynecol. 2016. Vol. 48. No. 3. P. 333–339. DOI: 10.1002/uog.15884

[37] Papageorghiou AT, Kennedy SH, Salomon LJ, et al. The INTERGROWTH-21st fetal growth standards: toward the global integration of pregnancy and pediatric care. Am J Obstet Gynecol. 2018;218(2S):S630–S640. DOI: 10.1016/j.ajog.2018.01.011

[38] Papageorghiou A.T., Kennedy S.H., Salomon L.J., et al. The INTERGROWTH-21st fetal growth standards: toward the global integration of pregnancy and pediatric care // Am. J. Obstet. Gynecol. 2018. Vol. 218. No. 2S. P. S630–S640. DOI: 10.1016/j.ajog.2018.01.011

[39] Papageorghiou AT, Ohuma EO, Altman DG, et al. International standards for fetal growth based on serial ultrasound measurements: the Fetal Growth Longitudinal Study of the INTERGROWTH-21st Project. Lancet. 2014;384(9946):869–879. DOI: 10.1016/S0140-6736(14)61490-2

[40] Papageorghiou A.T., Ohuma E.O., Altman D.G., et al. International standards for fetal growth based on serial ultrasound measurements: the Fetal Growth Longitudinal Study of the INTERGROWTH-21st Project // Lancet. 2014. Vol. 384(9946). P. 869–879. DOI: 10.1016/S0140-6736(14)61490-2

[41] Golic M, Stojanovska V, Bendix I, et al. Diabetes mellitus in pregnancy leads to growth restriction and epigenetic modification of the srebf2 gene in rat fetuses. Hypertension. 2018; 71(5):911–920. DOI: 10.1161/HYPERTENSIONAHA.117.10782

[42] Golic M., Stojanovska V., Bendix I., et al. Diabetes mellitus in pregnancy leads to growth restriction and epigenetic modification of the srebf2 gene in rat fetuses // Hypertension. 2018. Vol. 71. No. 5. P. 911–920. DOI: 10.1161/HYPERTENSIONAHA.117.10782

[43] Persson M, Shah PS, Rusconi F, et al. Association of maternal diabetes with neonatal outcomes of very preterm and very low-birth-weight infants: an international cohort study. JAMA Pediatr. 2018;172(9):867–875. DOI: 10.1001/jamapediatrics.2018.1811

[44] Persson M., Shah P.S., Rusconi F., et al. Association of maternal diabetes with neonatal outcomes of very preterm and very low-Birth-Weight infants: an international cohort study // JAMA Pediatr. 2018. Vol. 172. No. 9. P. 867–875. DOI: 10.1001/jamapediatrics.2018.1811.

[45] Sobrevia L, Abarzúa F, Nien JK, et al. Review: differential placental macrovascular and microvascular endothelial dysfunction in gestational diabetes. Placenta. 2011;32(Suppl. 2):S159–S164. DOI: 10.1016/j.placenta.2010.12.011

[46] Sobrevia L., Abarzúa F., Nien J.K., et al. Review: differential placental macrovascular and microvascular endothelial dysfunction in gestational diabetes // Placenta. 2011. Vol. 32. No. 2, Suppl. P. S159–S164. DOI: 10.1016/j.placenta.2010.12.011

[47] Relph S, Patel T, Delaney L, et al. Adverse pregnancy outcomes in women with diabetes-related microvascular disease and risks of disease progression in pregnancy: a systematic review and meta-analysis. PLoS Med. 2021;18(11). DOI: 10.1371/journal.pmed.1003856

[48] Relph S., Patel T., Delaney L., et al. Adverse pregnancy outcomes in women with diabetes-related microvascular disease and risks of disease progression in pregnancy: a systematic review and meta-analysis // PLoS Med. 2021. Vol. 8. No. 11. DOI: 10.1371/journal.pmed.1003856

[49] Morikawa M, Kato-Hirayama E, Mayama M, et al. Glycemic control and fetal growth of women with diabetes mellitus and subsequent hypertensive disorders of pregnancy. PLoS One. 2020;15(3). DOI: 10.1371/journal.pone.0230488

[50] Morikawa M., Kato-Hirayama E., Mayama M., et al. Glycemic control and fetal growth of women with diabetes mellitus and subsequent hypertensive disorders of pregnancy // PLoS One. 2020. Vol. 15. No. 3. DOI: 10.1371/journal.pone.0230488

[51] Herzog EM, Eggink AJ, Reijnierse A, et al. Impact of early- and late-onset preeclampsia on features of placental and newborn vascular health. Placenta. 2017; 49:72–79. DOI: 10.1016/j.placenta.2016.11.014

[52] Herzog E.M., Eggink A.J., Reijnierse A., et al. Impact of early- and late-onset preeclampsia on features of placental and newborn vascular health // Placenta. 2017. Vol. 49. P. 72–79. DOI: 10.1016/j.placenta.2016.11.014

[53] Phipps E, Prasanna D, Brima W, et al. Preeclampsia: updates in pathogenesis, definitions, and guidelines. Clin J Am Soc Nephrol. 2016;11(6):1102–1113. DOI: 10.2215/CJN.12081115

[54] Phipps E., Prasanna D., Brima W., et al. Preeclampsia: updates in pathogenesis, definitions, and guidelines // Clin. J. Am. Soc. Nephrol. 2016. Vol. 11. No. 6. P. 1102–1113. DOI: 10.2215/CJN.12081115

[55] Bokslag A, van Weissenbruch M, Mol BW, et al. Preeclampsia; short and long-term consequences for mother and neonate. Early Hum Dev. 2016;102:47–50. DOI: 10.1016/j.earlhumdev.2016.09.007.

[56] Bokslag A., van Weissenbruch M., Mol B.W., et al. Preeclampsia; short and long-term consequences for mother and neonate // Early Hum. Dev. 2016. Vol. 102. P. 47–50. DOI: 10.1016/j.earlhumdev.2016.09.007

[57] Lees C, Marlow N, Arabin B, et al; TRUFFLE Group. Perinatal morbidity and mortality in early-onset fetal growth restriction: cohort outcomes of the trial of randomized umbilical and fetal flow in Europe (TRUFFLE). Ultrasound Obstet Gynecol. 2013;42(4):400–408. DOI: 10.1002/uog.13190

[58] Lees C., Marlow N., Arabin B., et al.; TRUFFLE Group. Perinatal morbidity and mortality in early-onset fetal growth restriction: cohort outcomes of the trial of randomized umbilical and fetal flow in Europe (TRUFFLE) // Ultrasound Obstet. Gynecol. 2013. Vol. 42. No. 4. P. 400–408. DOI: 10.1002/uog.13190

[59] Gaudineau A. Prevalence, risk factors, maternal and fetal morbidity and mortality of intrauterine growth restriction and small-for-gestational age. J Gynecol Obstet Biol Reprod. 2013;42(8):895–910. DOI: 0.1016/j.jgyn.2013.09.013

[60] Gaudineau A. Prevalence, risk factors, maternal and fetal morbidity and mortality of intrauterine growth restriction and small-for-gestational age // J. Gynecol. Obstet. Biol. Reprod. 2013. Vol. 42. No. 8. P. 895–910. DOI: 0.1016/j.jgyn.2013.09.013

[61] Bedell S, Hutson J, de Vrijer B, et al. Effects of maternal obesity and gestational diabetes mellitus on the placenta: current knowledge and targets for therapeutic interventions. Curr Vasc Pharmacol. 2021;19(2):176–192. DOI: 10.2174/1570161118666200616144512

[62] Bedell S., Hutson J., de Vrijer B., et al. Effects of maternal obesity and gestational diabetes mellitus on the placenta: current knowledge and targets for therapeutic interventions // Curr. Vasc. Pharmacol. 2021. Vol. 19. No. 2. P. 176–192. DOI: 10.2174/1570161118666200616144512

[63] Tanner LD, Brock And C, Chauhan SP. Severity of fetal growth restriction stratified according to maternal obesity. J Matern Fetal Neonatal Med. 2022;35(10):1886–1890. DOI: 10.1080/14767058.2020.1773427

[64] Tanner L.D., Brock And C., Chauhan S.P. Severity of fetal growth restriction stratified according to maternal obesity // J. Matern. Fetal Neonatal. Med. 2022. Vol. 35. No. 10. P. 1886–1890. DOI: 10.1080/14767058.2020.1773427

[65] GRIT Study Group. A randomised trial of timed delivery for the compromised preterm fetus: short term outcomes and Bayesian interpretation. BJOG. 2003;110(1):27–32. DOI: 10.1016/s1470-0328(02)02514-4

[66] GRIT Study Group. A randomised trial of timed delivery for the compromised preterm fetus: short term outcomes and Bayesian interpretation // BJOG. 2003. Vol. 110. No. 1. P. 27–32. DOI: 10.1016/s1470-0328(02)02514-4

[67] Kapustin RV, Kopteeva EV, Alexeenkova EN, et al. Analysis of risk factors and perinatal mortality structure in pregnant patients with diabetes mellitus. Doctor.Ru. 2021;20(6):46–52. (In Russ.). DOI: 10.31550/1727-2378-2021-20-6-46-52

[68] Капустин Р.В., Коптеева Е.В., Алексеенкова Е.Н., и др. Анализ факторов риска и структуры перинатальных потерь у беременных с сахарным диабетом // Доктор.Ру. 2021. Т. 20. №. 6. С. 46–52. DOI: 10.31550/1727-2378-2021-20-6-46-52

[69] Morsing E, Brodszki J, Thuring A, et al. Infant outcome after active management of early-onset fetal growth restriction with absent or reversed umbilical artery blood flow. Ultrasound Obstet Gynecol. 2021;57(6):931–941. DOI: 10.1002/uog.23101

[70] Morsing E., Brodszki J., Thuring A., et al. Infant outcome after active management of early-onset fetal growth restriction with absent or reversed umbilical artery blood flow // Ultrasound Obstet. Gynecol. 2021. Vol. 57. No. 6. P. 931–941. DOI: 10.1002/uog.23101

[71] Vasak B, Koenen SV, Koster MP, et al. Human fetal growth is constrained below optimal for perinatal survival. Ultrasound Obstet Gynecol. 2015;45(2):162–167. DOI: 10.1002/uog.14644

[72] Vasak B., Koenen S.V., Koster M.P., et al. Human fetal growth is constrained below optimal for perinatal survival // Ultrasound Obstet. Gynecol. 2015. Vol. 45. No. 2. P. 162–17. DOI: 10.1002/uog.14644

[73] King VJ, Bennet L, Stone PR, et al. Fetal growth restriction and stillbirth: biomarkers for identifying at risk fetuses. Front Physiol. 2022;13. DOI: 10.3389/fphys.2022.959750

[74] King V.J., Bennet L., Stone P.R., et al. Fetal growth restriction and stillbirth: Biomarkers for identifying at risk fetuses // Front. Physiol. 2022. Vol. 13. DOI: 10.3389/fphys.2022.959750

[75] Dall’Asta A, Brunelli V, Prefumo F, et al. Early onset fetal growth restriction. Matern Health Neonatol Perinatol. 2017;3. DOI: 10.1186/s40748-016-0041-x

[76] Dall’Asta A., Brunelli V., Prefumo F., et al. Early onset fetal growth restriction // Matern. Health Neonatol. Perinatol. 2017. Vol. 3. DOI: 10.1186/s40748-016-0041-x

[77] Kinoshita M, Thuring A, Morsing E, et al. Extent of absent end-diastolic flow in umbilical artery and outcome of pregnancy. Ultrasound Obstet Gynecol. 2021;58(3):369–376. DOI: 10.1002/uog.23541

[78] Kinoshita M., Thuring A., Morsing E., et al. Extent of absent end-diastolic flow in umbilical artery and outcome of pregnancy // Ultrasound Obstet. Gynecol. 2021. Vol. 58. No. 3. P. 369–376. DOI: 10.1002/uog.23541

[79] Lees CC, Stampalija T, Baschat A, et al. ISUOG practice guidelines: diagnosis and management of small-for-gestational-age fetus and fetal growth restriction. Ultrasound Obstet Gynecol. 2020;56(2):298–312. DOI: 10.1002/uog.22134

[80] Lees C.C., Stampalija T., Baschat A., et al. ISUOG practice guidelines: diagnosis and management of small-for-gestational-age fetus and fetal growth restriction // Ultrasound Obstet. Gynecol. 2020. Vol. 56. No. 2. P. 298–312. DOI: 10.1002/uog.22134

[81] Gairabekova D, van Rosmalen J, Duvekot JJ. Outcome of early-onset fetal growth restriction with or without abnormal umbilical artery Doppler flow. Acta Obstet Gynecol Scand. 2021;100(8):1430–1438. DOI: 10.1111/aogs.1414

[82] Gairabekova D., van Rosmalen J., Duvekot J.J. Outcome of early-onset fetal growth restriction with or without abnormal umbilical artery Doppler flow // Acta Obstet. Gynecol. Scand. 2021. Vol. 100. No. 8. P. 1430–1438. DOI: 10.1111/aogs.1414

RIGHTS & PERMISSIONS

Eсо-Vector